Subchronic exposure of [3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female B6C3F1 mice: Relationship of steady-state levels of disposition and metabolism

Toxicological Sciences

Volumn 61, Issue 2, 2001, Pages 241-255

  Diliberto, Janet J ^a   DeVito, Michael J ^a   Ross, David G ^a   Birnbaum, Linda S ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Body burden; CYP1A1; CYP1A2; Dioxin; Disposition; Dosimetry; Subchronic dosing; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CYTOCHROME P450 1A1; FAT; CYTOCHROME P450 1A2; DIAGNOSTIC AGENT; TRITIUM;

ANIMAL TISSUE; ARTICLE; BODY BURDEN; BODY WEIGHT; CAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIETARY INTAKE; DOSIMETRY; ENZYME ACTIVITY; EXPOSURE; FEMALE; LIVER; METABOLISM; MOUSE; NONHUMAN; RADIOACTIVITY; STEADY STATE; TIME; TOXICOKINETICS; ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMAL; CHEMISTRY; DIET; DOSE RESPONSE; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LUNG; MOUSE STRAIN; ORGAN SIZE; SKIN; STATISTICS; TISSUE DISTRIBUTION; URINE;

ANIMALIA;

ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMALS; BODY BURDEN; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FECES; FEMALE; LUNG; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; ORGAN SIZE; SKIN; STATISTICS; TETRACHLORODIBENZODIOXIN; TIME FACTORS; TISSUE DISTRIBUTION; TRITIUM; URINE;

EID: 0034743702     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/61.2.241     Document Type: Article

References (72)

1. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: 1. Dose-dependent tissue distribution and induction of hepatic ethoxyresorufin O-deethylase in rats following a single injection
2. Toxic equivalency factors for dioxin-like PCBs: Report on a WHO-ECEH and IPCS consultation December 1993
3. Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation
4. A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s
5. Modeling receptor-mediated process with dioxin: Implications for pharmacokinetics and risk assessment
6. Dose-dependent acinar induction of cytochrome P450 in rat liver. Evidence for a differential mechanism of induction of P450IA1 by b-naphthoflavone and dioxin
7. Distribution and excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin in congenic strains of mice which differ at the Ah locus
8. Evidence for the role of the Ah receptor in response to dioxin
9. The mechanism of dioxin toxicity: Relationship to risk assessment
10. A practical approach to a real-world problem
11. The use of toxic equivalency factors for risk assessment for dioxins and related compounds
12. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
13. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. I. Nonlinear distribution of PCDD/PCDF body burden between liver and adipose tissues
14. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammals, including humans. II. Kinetics of absorption and disposition of PCDDs/PCDFs
15. 2,3,7,8-tetrachlorodibenzo-p-dioxin pretreatment of female mice altered tissue distribution but not hepatic metabolism of a subsequent dose
16. Relationship between CYP1A enzyme activities and protein levels in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin
17. The importance of pharmacokinetics in determining the relative potency of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran
18. Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD to body burdens in experimentally exposed animals
19. Dose-response relationships for polyhalogenated dioxins and dibenzofurans following subchronic treatment in mice. I. CYP1A1 and CYP1A2 enzyme activity in liver, lung and skin
20. Dose-response relationships in mice following subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin: CYP1A1, CYP1A2, estrogen receptor and protein tyrosine phosphorylation
21. Comparative ability of various PCBs, PCDFs, and TCDD to induce cytochrome P450 1A1 and 1A2 activity following 4 weeks of treatment
22. Dose-response relationship for induction of CYP1A1 and CYP1A2 enzyme activity in liver, lung, and skin in female mice following subchronic exposure to polychlorinated biphenyls
23. Dose-response relationships for disposition and hepatic sequestration of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls following subchronic treatment in mice
24. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice
25. Effects of CYP1A2 on disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2′,4,4,′5,5′-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice
26. Role of CYP1A2 in hepatic sequestration of dioxin: Studies using CYP1A2 knock-out mice
27. Comparison of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) disposition following pulmonar, oral, dermal, and parenteral exposures to rats
28. 3H]tetrabromodibenzo-p-dioxin (TBDD) in the rat
29. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): Assessing the impact of specific model parameters on sequestration in liver and fat in the rat
30. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor
31. Elimination of polychlorinated dibenzo-p-dioxins and dibenzofurans in occupationally exposed persons
32. Dioxins and diet: A real risk?
33. Distribution, excretion, and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J, DBA/2J, and B6D2F1/J mice
34. Evidence of hepatic sequestration of dioxins in humans? An examination of tissue levels and CYP1A2 expression
35. Exposures and risks of dioxin in the U.S. food supply
36. Effects of age, sex, and pharmacologic agents on the biliary elimination of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in F344 rats
37. Estimation of octanol-water partition coefficients and correlation with dermal absorption for several polyhalogenated aromatic hydrocarbons
38. Disposition and excretion of intravenous 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in rats
39. Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species
40. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. 2. Pharmacokinetics in rats using a loading-dose/maintenance-dose regime with high doses
41. Studies on the mechanism of absorption and distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat
42. 125I]-2-iodo-3,7,8-trichlorobdibenzo-p-dioxin in mice: Analysis with a physiological modeling approach
43. Relative distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatic and adipose tissues
44. Subchronic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and their reversibility in male Sprague-Dawley rats
45. Role of cytochrome P450 1A2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies
46. Pharmacokinetics of TCDD in veterans of Operation Ranch Hand: 15-year follow-up
47. The toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mammalian systems
48. Half-life of 2,3,7,8-tetrachlorodibenzo-p-dioxin in serum of Seveso adults: Interim report
49. Metabolism and disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin in guinea pigs
50. Tissue distribution, excretion, and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the Golden Syrian hamster
51. A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions
52. Pharmacokinetics of 2,3,7,8-TCDD in man
53. 125I]-2-iodo-3,7,8-trichlorobdibenzo-p-dioxin binding species in mouse liver induced by agonists for the Ah receptor: Characterization and identification
54. 125I]-2-iodo-3,7,8-trichlorobdibenzo-p-dioxin by the administration of agonists for the Ah receptor
55. The fate of 2,3,7,8-tetrachlorodibenzo-p-dioxin following single and repeated oral doses to the rat
56. Tissue distribution of dioxins and furans in humans from the general population
57. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs), and related compounds: Environmental and mechanistic considerations which support the development of toxic equivalency factors (TEFs)
58. A pharmacodynamic analysis of TCDD-induced cytochrome P-450 gene expression in multiple tissues: Dose- and time-dependent effects
59. Digestive tract absorption of PCDD/Fs, PCBs, and HCB in humans: Mass balances and mechanistic considerations
60. Relationship between the murine Ah phenotype and the hepatic uptake and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin
61. Concentrations of PCDD and PCDF in human fat and liver samples
62. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: Quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver
63. Human exposure to dioxin
64. Relative potencies of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls derived from hepatic porphyrin accumulation in mice
65. The toxicokinetics and metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) and their relevance for toxicity
66. Environmental toxicology of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans
67. A generic toxicokinetic model for persistent lipophilic compounds in humans: An application to TCDD
68. Effect of subchronic 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on immune system and target gene responses in mice: Calculation of benchmark doses for CYP1A1 and CYP1A2 related enzyme activities
69. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species
70. Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats
71. 3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin in human feces to ascertain its relative metabolism in man